The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Josefina Serrano et al.|Blood|2023Cited by 15
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha et al.|Cancers|2021Cited by 12
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Enhanced Validation of the <i>FLT3</i>-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in <i>FLT3-ITD</i> Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2024Cited by 3
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic RegistryDavid Martínez‐Cuadrón, Pau Montesinos, Blanca Boluda et al.|Blood|2023Cited by 2